Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

por Engel, Samuel S., Round, Elizabeth, Golm, Gregory T., Kaufman, Keith D., Goldstein, Barry J.
Publicado em 2013

Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

por Engel, Samuel S., Round, Elizabeth, Golm, Gregory T., Kaufman, Keith D., Goldstein, Barry J.
Publicado em 2013

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

por Engel Samuel S, Golm Gregory T, Shapiro Deborah, Davies Michael J, Kaufman Keith D, Goldstein Barry J
Publicado em 2013-01-01

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

por Engel, Samuel S, Golm, Gregory T, Shapiro, Deborah, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J
Publicado em 2013

Erratum to: Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials

por Ommen, Elizabeth S., Xu, Lei, O’Neill, Edward A., Goldstein, Barry J., Kaufman, Keith D., Engel, Samuel S.
Publicado no Diabetes Ther (2015)

Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials

por Ommen, Elizabeth S., Xu, Lei, O’Neill, Edward A., Goldstein, Barry J., Kaufman, Keith D., Engel, Samuel S.
Publicado no Diabetes Ther (2015)

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency

por Raji, Annaswamy, Xu, Zhi Jin, Lam, Raymond L. H., O’Neill, Edward A., Kaufman, Keith D., Engel, Samuel S.
Publicado no Diabetes Ther (2020)

A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2...

por Gantz, Ira, Okamoto, Taro, Ito, Yuka, Okuyama, Kotoba, O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Publicado no Diabetes Obes Metab (2017)

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

por Williams-Herman, Debora, Round, Elizabeth, Swern, Arlene S, Musser, Bret, Davies, Michael J, Stein, Peter P, Kaufman, Keith D, Amatruda, John M
Publicado em 2008

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

por Gantz, Ira, Chen, Menghui, Suryawanshi, Shailaja, Ntabadde, Catherine, Shah, Sukrut, O’Neill, Edward A., Engel, Samuel S., Kaufman, Keith D., Lai, Eseng
Publicado no Cardiovasc Diabetol (2017)

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoS...

por Scott, Russell, Morgan, Jerry, Zimmer, Zachary, Lam, Raymond L. H., O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Raji, Annaswamy
Publicado no Diabetes Obes Metab (2018)

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

por Meininger, Gary E., Scott, Russell, Alba, Maria, Shentu, Yue, Luo, Edmund, Amin, Himal, Davies, Michael J., Kaufman, Keith D., Goldstein, Barry J.
Publicado em 2011

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

por Arjona Ferreira, Juan Camilo, Marre, Michel, Barzilai, Nir, Guo, Hua, Golm, Gregory T., Sisk, Christine McCrary, Kaufman, Keith D., Goldstein, Barry J.
Publicado em 2013

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

por Mathieu, Chantal, Shankar, R. Ravi, Lorber, Daniel, Umpierrez, Guillermo, Wu, Fan, Xu, Lei, Golm, Gregory T., Latham, Melanie, Kaufman, Keith D., Engel, Samuel S.
Publicado no Diabetes Ther (2015)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibito...

por Goldenberg, Ronald, Gantz, Ira, Andryuk, Paula J., O'Neill, Edward A., Kaufman, Keith D., Lai, Eseng, Wang, Yin Na, Suryawanshi, Shailaja, Engel, Samuel S.
Publicado no Diabetes Obes Metab (2017)

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequ...

por Lee, Seung-Hwan, Gantz, Ira, Round, Elizabeth, Latham, Melanie, O’Neill, Edward A., Ceesay, Paulette, Suryawanshi, Shailaja, Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Publicado no BMC Endocr Disord (2017)

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

por Williams-Herman, Debora, Engel, Samuel S, Round, Elizabeth, Johnson, Jeremy, Golm, Gregory T, Guo, Hua, Musser, Bret J, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J
Publicado em 2010

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus

por Ji, Linong, Han, Ping, Wang, Xiaoyue, Liu, Jingdong, Zheng, Shaoxiong, Jou, Ying‐Ming, O'Neill, Edward A, Golm, Gregory T, Engel, Samuel S, Kaufman, Keith D, Shankar, R Ravi
Publicado no J Diabetes Investig (2016)

Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 d...

por Frias, Juan P., Zimmer, Zachary, Lam, Raymond L.H., Amorin, Guillermo, Ntabadde, Catherine, Iredale, Carol, O'Neill, Edward A., Engel, Samuel S., Kaufman, Keith D., Makimura, Hideo, Crutchlow, Michael F.
Publicado no Diabetes Obes Metab (2019)

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin gl...

por Roussel, Ronan, Duran‐García, Santiago, Zhang, Yilong, Shah, Suneri, Darmiento, Carolyn, Shankar, R. Ravi, Golm, Gregory T., Lam, Raymond L. H., O'Neill, Edward A., Gantz, Ira, Kaufman, Keith D., Engel, Samuel S.
Publicado no Diabetes Obes Metab (2018)